Ambeed.cn

首页 / 抑制剂/激动剂 / / 雄激素受体 / Enzalutamide

恩杂鲁胺 /Enzalutamide {[allProObj[0].p_purity_real_show]}

货号:A270395 同义名: MDV3100

Enzalutamide(MDV3100) 是一种雄激素受体 (AR) 拮抗剂,在 LNCaP 前列腺细胞中的 IC50 为 36 nM。它还可以激活自噬

Enzalutamide 化学结构 CAS号:915087-33-1
Enzalutamide 化学结构
CAS号:915087-33-1
Enzalutamide 3D分子结构
CAS号:915087-33-1
Enzalutamide 化学结构 CAS号:915087-33-1
Enzalutamide 3D分子结构 CAS号:915087-33-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Enzalutamide 纯度/质量文件 产品仅供科研

货号:A270395 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell Host Microbe, 2024. Ambeed. [ A163338 ]
Cancer Res., 2024. Ambeed. [ A295334 ]
J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 Androgen Receptor 其他靶点 纯度
Cyproterone acetate ++++

Androgen Receptor, IC50: 7.1 nM

98%
Apalutamide +++

Androgen Receptor, IC50: 16 nM

98%
AZD3514 +

Androgen Receptor, Ki: 2.2 μM

98%
Darolutamide ++++

Androgen receptor, Ki: 11 nM

98%
Flutamide +++

Androgen Receptor, Ki: 55 nM

98%
Galeterone ++

Androgen Receptor, IC50: 384 nM

98%
Enzalutamide +++

Androgen Receptor, IC50: 36 nM

98%
Megestrol 98%
Bicalutamide ++

Androgen Receptor, IC50: 0.16 μM

99%
EPI-001 +

Androgen Receptor, IC50: ~6 μM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Enzalutamide 生物活性

靶点
  • Androgen Receptor

    Androgen Receptor, IC50:36 nM

描述 The androgen receptor (AR), also known as NR3C4, is one kind of nuclear receptor. When binding either of androgenic hormones, testosterone or dihydrotestosterone, androgen receptor can be activated and translocate into the nucleus. Increased androgen receptor gene expression may critically influence cancer progression such as, prostate cancer[1]. Enzalutamide, also called as MDV3100, is an androgen-receptor (AR) antagonist with IC50 of 36 nM (measured by relative AR binding affinity)[1]. Enzalutamide can prevent nuclear translocation and impair DNA binding of AR induced by R1881 (a synthetic androgen)[1], which facilitated mediating reduced PSA levels in AR-positive prostate cancer cell line (LNCaP) and inhibiting the growth of LNCaP cells[3]. Enzalutamide is the first approved second-generation androgen receptor (AR) antagonist in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and shows good pharmacokinetic profiles in human[4] as well as animal[5].
作用机制 Enzalutamide is a competitive inhibitor of AR ligand binding.[6]

Enzalutamide 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
BCK4 10 μM Function Assay 7 days Inhibits estradiol-mediated proliferation 24451109
CWR22Rv1 15 μM Function Assay 24 h Does not affect the full length AR expression 23713567
human LNCAP Cytotoxic Assay 7 days IC50=5.12 μM 23713567
human LNCAP 1 μM Function Assay Inhibits prostate specific antigen secretion in human LNCAP cells expressing androgen receptor at 100-1000nM 20218717

Enzalutamide 动物研究

Dose Mice: min = 10 mg/kg[7], max = 60 mg/kg[8]
Administration p.o.

Enzalutamide 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01650194 Metastatic Castration-Resistan... 展开 >>t Prostate Cancer 收起 << Phase 2 Completed - United States, Texas ... 展开 >> Site US2492 MD Anderson Cancer Ctr Houston, Texas, United States, 77030 收起 <<
NCT03478904 Prostate Cancer Phase 1 Recruiting April 30, 2019 United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 收起 <<
NCT03305224 Castration-resistant Prostate ... 展开 >>Cancer Bone Metastases 收起 << Phase 2 Recruiting December 2019 Japan ... 展开 >> Osaka City University Graduate School of Medicine Recruiting Osaka, Japan, 545-8585 Contact: Taro Iguchi, MD, PhD 收起 <<

Enzalutamide 参考文献

[1]Tran C, Ouk S, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787-90.

[2]Saraon P, Jarvi K, et al. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 2011 Oct;57(10):1366-75.

[3]Ardiani A, Gameiro SR, et al. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014 Oct 15;5(19):9335-48.

[4]Hong JH, et al. Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):361-369.

[5]Kim TH, Jeong JW, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38(11):2076-82.

[6]Golshayan AR, Antonarakis ES, et al. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid. 2013;8:27-35.

Enzalutamide 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.22mL

10.77mL

2.15mL

1.08mL

21.53mL

4.31mL

2.15mL

Enzalutamide 技术信息

CAS号915087-33-1
分子式C21H16F4N4O2S
分子量 464.436
别名 MDV3100
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Room temperature

溶解度

DMSO: 50 mg/mL(107.66 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 3 mg/mL clear

PO 0.5% CMC-Na 50 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。